Anteris welcomes successful DurAVR valve-in-valve procedure | News Direct

Anteris welcomes successful DurAVR valve-in-valve procedure

Anteris Technologies Ltd
News release by Anteris Technologies Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | August 01, 2023 12:00 PM Eastern Daylight Time

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson tells Proactive the company’s flagship transcatheter heart valve has been successfully implanted during a valve-in-valve procedure as part of Health Canada’s Special Access Program (SAP).

The procedure is used in life-threatening situations where a patient’s bioprosthetic aortic valve is failing due to calcification or structural deterioration, meaning a new heart valve must be implanted inside the failing valve. Paterson says the successful procedure further validates the company’s extensive pre-clinical valve-in-valve work as well as its clinical experience in native aortic stenosis.

Dr Anita Asgar, co-director of the Structural Heart Program at the Institut de Cardiologie de Montreal, asked to use the DurAVR valve given the need for optimal hemodynamic results.

Dr Asgar said using Anteris’ ComASUR™ delivery system and deploying the valve was remarkably easy.

“The unique design of DurAVR, including the low frame height and the single-piece design, makes the valve well-suited to address the needs of valve-in-valve patients,” she concluded.



Contact Details


Proactive Investors


Jonathan Jackson


+61 413 713 744

project media


Anteris Technologies LtdbiotechAsxproactiveAustraliaproactiveInvestors